Condition: Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment · Sponsor: Alpha Biopharma (Jiangsu) Co., Ltd.
This is a clinical trial that aims to test Zorifertinib when used together with a known drug, Osimertinib. The goal is to learn if this combination is safe and works for people with advanced Non-Small Cell Lung Cancer (NSCLC) whose cancer has spread to the membranes surrounding the brain and spinal cord (a condition called leptomeningeal metastases) after being treated with Osimertinib.
This description comes directly from the study's public registry record.
John Ge, M.D · +86 (0)21-63862197 · john.ge@alphabiopharma.com.cn
Always discuss trial participation with your own doctor first.
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | Recruiting |
| The First Affiliated Hospital of China Medical University | Shengyang, City, China | Recruiting |
| Chinese Academy of Medical Sciences Cancer Hospital Shenzhen Hospital | Guangzhou, Province, China | Recruiting |
| Henan Cancer Hospital | Henan, Province, China | Recruiting |
| Shanxi Cancer Hospital | Shanxi, Province, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07361705